Acadia Healthcare Company, Inc.

Acadia Healthcare Company, Inc. (ACHC) Stock Analysis

$28.550

-1.579 (-5.53%)At close

Loading chart…
High
30.350
Open
30.150
VWAP
29.09
Vol
1.23M
Mkt Cap
6.31B
Low
28.380
Amount
35.66M
EV/EBITDA, TTM
8.96

Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services. The Company owns and operates acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers (CTCs), residential treatment centers and facilities providing outpatient behavioral healthcare services to serve the behavioral healthcare and recovery needs of communities throughout the United States and Puerto Rico. Its acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. Its CTCs specialize in providing medication-assisted treatment in an outpatient setting. Its specialty treatment facilities primarily consist of residential recovery facilities. It provides a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders. Its residential treatment centers treat patients with behavioral disorders in a non-hospital setting.

AI analysis of Acadia Healthcare Company, Inc. (ACHC)

hold

Acadia Healthcare is currently priced at $28.55, which is significantly below the analyst price target of $39 from Guggenheim, suggesting potential upside. However, the company has a troubling forward P/E of 21.41, indicating that it may be overvalued relative to its earnings prospects. Additionally, insider selling has increased by 194.77% over the last quarter, which raises concerns about management's confidence in the company's future. Therefore, while there is potential for growth, the risks associated with current performance and insider activity suggest a cautious approach.

Analyst Ratings (17)

-36.60% downside
Buy
10 Buy
7 Hold
0 Sell
Current: 28.55
Low
13.00
Average
18.10
High
25.00

Guggenheim

2026-07-30

Price Target

$39

Buy

Barclays

2026-07-30

Price Target

$32

Equal Weight

BofA

2026-07-29

Price Target

$13

Underperform

Guggenheim

2026-07-20

Price Target

$38

Buy

KeyBanc

2026-07-14

Price Target

$40

Overweight

Valuation Metrics

The current forward P/E ratio for Acadia Healthcare Company, Inc. (ACHC) is 21.41, compared to its 5-year average forward P/E of 18.08.

Forward P/E

Fair
5Y Average P/E
18.08
Current P/E
21.41
Overvalued
23.78
Undervalued
12.39

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
9.89
Current EV/EBITDA
8.96
Overvalued
14.08
Undervalued
5.70

Forward P/S

Undervalued
5Y Average P/S
1.71
Current P/S
0.73
Overvalued
2.50
Undervalued
0.91

Alphio AI Price Scenarios for ACHC

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ACHC

$29.90

Scenario price

B

Base

Base · 50%ACHC

$25.39

Scenario price

B

Bear

Bear · 25%ACHC

$23.05

Scenario price

Whales holding ACHC

G

Greenlight Capital, Inc.

+ HoldingACHC

+3.43%

3M Return

P

Palisade Capital Management, LP

+ HoldingACHC

+2.87%

3M Return

ACHC FAQ — answered by Alphio AI

Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services. The Company owns and operates acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers (CTCs), residential treatment centers and facilities providing outpatient behavioral healthcare services to serve the behavioral healthcare and recovery needs of communities throughout the United States and Puerto Rico. Its acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. Its CTCs specialize in providing medication-assisted treatment in an outpatient setting. Its specialty treatment facilities primarily consist of residential recovery facilities. It provides a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders. Its residential treatment centers treat patients with behavioral disorders in a non-hospital setting. It operates in the Healthcare sector (SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC industry).

Acadia Healthcare is currently priced at $28.55, which is significantly below the analyst price target of $39 from Guggenheim, suggesting potential upside. However, the company has a troubling forward P/E of 21.41, indicating that it may be overvalued relative to its earnings prospects. Additionally, insider selling has increased by 194.77% over the last quarter, which raises concerns about management's confidence in the company's future. Therefore, while there is potential for growth, the risks associated with current performance and insider activity suggest a cautious approach.

17 analysts cover ACHC: 10 rate it Buy, 7 Hold and 0 Sell. The average price target is 18.10.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis